e-therapeutics plc
ETXPF
$0.13
-$0.01-7.14%
OTC PK
| 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -30.52% | -34.52% | -51.72% | -35.70% | 24.12% |
| Total Depreciation and Amortization | -6.60% | -3.76% | 15.79% | 3.56% | 36.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.03% | 52.41% | -148.88% | -122.63% | -12.64% |
| Change in Net Operating Assets | 46.33% | 50.81% | 59.28% | 63.57% | 267.94% |
| Cash from Operations | -28.29% | -32.22% | -50.09% | -34.24% | 37.89% |
| Capital Expenditure | -1,380.58% | -1,433.67% | 89.74% | 90.80% | 79.80% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -32.11% | -30.01% | -98.37% | -98.55% | 103.41% |
| Cash from Investing | -99.72% | -99.71% | -98.40% | -98.57% | 103.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 52.43% | 52.43% | -- | -- | -200.77% |
| Issuance of Common Stock | -99.89% | -99.89% | 175.00% | 175.00% | 103,200.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -101.37% | -101.41% | -2,530.61% | -2,267.92% | 1,631.59% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -143.14% | -144.46% | -169.27% | -161.95% | 165.08% |